Natco Pharma share news, announcements and annual reports
NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap
Natco Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Dec 1995 on NSE
Last close ₹782.40down ₹5.15 (0.65%)BSE ₹782.50
Share price at the NSE close on 30 Oct 2026. Previous close ₹787.55.
30 Oct: open ₹792.05, high ₹800.90, low ₹779.50
52-week range of traded prices to 30 Oct 2026
₹773.60Low, 22 Oct 2026₹1,226.80High, 12 May 2026
- Next results date: the board meets on 13 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,348 Cr380th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.58%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.08
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,21,54744.0% delivered
Natco Pharma share news and announcements
1,035 announcements, routine notices left out, newest first. Page 7 of 21.
Nov 2021
11 Nov · Corporate action
11 Nov · Results
9 Nov · Analysts
Oct 2021
Sep 2021
30 Sep · Meeting
Aug 2021
20 Aug · Legal
Exchange has sought clarification from Natco Pharma Limited with respect to announcement dated 20-Aug-2021, regarding its press release dated August 20, 2021. On basis of above the Company is required to clarify following: 1. Expected financial implications, if any, due to compensation, penalty etc;2. Quantum of claims, if anyThe response of the Company is awaited.12 Aug · Updates
12 Aug · Corporate action
12 Aug · Results
9 Aug · Analysts
Jul 2021
28 Jul · News Verification
The exchange asked on 27 Jul 2021
8 Jul · Legal
Exchange has sought clarification from Natco Pharma Limited with respect to announcement dated 07-Jul-2021, regarding a press release dated July 07, 2021, titled "legal update".On basis of above the Company is required to clarify following:1. Brief details of litigation viz. name(s) of the opposing party, court/ tribunal/agency where litigation is filed, brief details of dispute/litigation;2. Expected financial implications, if any, due to compensation, penalty etc;3. Quantum of claims, if any.The response of the Company is awaited.7 Jul · Business
Jun 2021
17 Jun · Results
14 Jun · Analysts
May 2021
Apr 2021
Mar 2021
26 Mar · Board meeting
Feb 2021
11 Feb · Results
11 Feb · Corporate action
8 Feb · Analysts